Departments of Pharmacology.
Biochemistry and Molecular Biology.
J Neurosci. 2019 Jun 26;39(26):5222-5233. doi: 10.1523/JNEUROSCI.2204-18.2019. Epub 2019 Apr 23.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces the production of granulocyte and macrophage populations from the hematopoietic progenitor cells; it is one of the most common growth factors in the blood. GM-CSF is also involved in bone cancer pain development by regulating tumor-nerve interactions, remodeling of peripheral nerves, and sensitization of damage-sensing (nociceptive) nerves. However, the precise mechanism for GM-CSF-dependent pain is unclear. In this study, we found that GM-CSF is highly expressed in human malignant osteosarcoma. Female Sprague Dawley rats implanted with bone cancer cells develop mechanical and thermal hyperalgesia, but antagonizing GM-CSF in these animals significantly reduced such hypersensitivity. The voltage-gated Na channels Nav1.7, Nav1.8, and Nav1.9 were found to be selectively upregulated in rat DRG neurons treated with GM-CSF, which resulted in enhanced excitability. GM-CSF activated the Janus kinase 2 (Jak2)-signal transducer and activator of transcription protein 3 (Stat3) signaling pathway, which promoted the transcription of Nav1.7-1.9 in DRG neurons. Accordingly, targeted knocking down of either Nav1.7-1.9 or Jak2/Stat3 in DRG neurons alleviated the hyperalgesia in male Sprague Dawley rats. Our findings describe a novel bone cancer pain mechanism and provide a new insight into the physiological and pathological functions of GM-CSF. It has been reported that granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in bone cancer pain, yet the underlying mechanisms involved in the GM-CSF-mediated signaling pathway in nociceptors is not fully understood. Here, we showed that GM-CSF promotes bone cancer-associated pain by enhancing the excitability of DRG neurons via the Janus kinase 2 (Jak2)-signal transducer and activator of transcription protein 3 (Stat3)-mediated upregulation of expression of nociceptor-specific voltage-gated sodium channels. Our study provides a detailed understanding of the roles that sodium channels and the Jak2/Stat3 pathway play in the GM-CSF-mediated bone cancer pain; our data also highlight the therapeutic potential of targeting GM-CSF.
粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 可诱导造血祖细胞产生粒细胞和巨噬细胞群体; 它是血液中最常见的生长因子之一。GM-CSF 通过调节肿瘤-神经相互作用、外周神经重塑和伤害感受 (痛觉) 神经的敏化,也参与骨癌痛的发展。然而,GM-CSF 依赖性疼痛的确切机制尚不清楚。在这项研究中,我们发现 GM-CSF 在人类恶性骨肉瘤中高度表达。植入骨肉瘤细胞的雌性 Sprague Dawley 大鼠会出现机械性和热痛觉过敏,但在这些动物中拮抗 GM-CSF 可显著减轻这种过敏反应。研究发现,GM-CSF 处理的大鼠 DRG 神经元中电压门控钠通道 Nav1.7、Nav1.8 和 Nav1.9 选择性地上调,导致兴奋性增强。GM-CSF 激活了 Janus 激酶 2 (Jak2)-信号转导和转录激活因子 3 (Stat3) 信号通路,促进了 DRG 神经元中 Nav1.7-1.9 的转录。因此,在 DRG 神经元中靶向敲低 Nav1.7-1.9 或 Jak2/Stat3 可缓解雄性 Sprague Dawley 大鼠的痛觉过敏。我们的研究结果描述了一种新的骨癌痛机制,并为 GM-CSF 的生理和病理功能提供了新的见解。据报道,粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 在骨癌痛中起关键作用,但 GM-CSF 介导的伤害感受器信号通路的潜在机制尚不完全清楚。在这里,我们通过证明 GM-CSF 通过 Janus 激酶 2 (Jak2)-信号转导和转录激活因子 3 (Stat3) 介导的伤害感受器特异性电压门控钠通道表达的上调来增强 DRG 神经元的兴奋性,从而促进与骨癌相关的疼痛。我们的研究提供了对钠通道和 Jak2/Stat3 通路在 GM-CSF 介导的骨癌痛中的作用的详细了解; 我们的数据还突出了靶向 GM-CSF 的治疗潜力。